La Jolla Pharmaceutical (LJPC) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2020	Jul. 27, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-36282
Entity Registrant Name	LA JOLLA PHARMACEUTICAL COMPANY
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	33-0361285
Entity Address, Address Line One	4550 Towne Centre Court,
Entity Address, City or Town	San Diego,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	207-4264
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	LJPC
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Shell Company	false
Entity Common Stock, Shares Outstanding		27,362,100
Entity Central Index Key	0000920465
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 68,353	$ 87,820
Short-term investments	3,062	0
Accounts receivable, net	1,843	2,960
Inventory, net	3,120	2,211
Prepaid expenses and other current assets	2,792	4,467
Total current assets	79,170	97,458
Property and equipment, net	12,827	18,389
Right-of-use lease asset	14,792	15,491
Restricted cash	606	909
Total assets	107,395	132,247
Current liabilities:
Accounts payable	2,481	4,177
Accrued expenses	6,772	9,312
Accrued payroll and related expenses	5,741	8,332
Lease liability, current portion	2,890	2,766
Total current liabilities	17,884	24,587
Lease liability, less current portion	25,000	26,481
Deferred royalty obligation, net	124,406	124,379
Other noncurrent liabilities	15,317	12,790
Total liabilities	182,607	188,237
Shareholders’ deficit:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,358,611 and 27,195,469 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	3	3
Additional paid-in capital	982,393	977,432
Accumulated deficit	(1,061,514)	(1,037,331)
Total shareholders’ deficit	(75,212)	(55,990)
Total liabilities and shareholders’ deficit	107,395	132,247
Series C-1 Convertible Preferred Stock [Member]
Shareholders’ deficit:
Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2020 and December 31, 2019; and liquidation preference of $3,906 at June 30, 2020 and December 31, 2019	$ 3,906	$ 3,906

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,358,611	27,195,469
Common stock, shares outstanding (in shares)	27,358,611	27,195,469
Series C-1 Convertible Preferred Stock [Member]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	11,000	11,000
Preferred stock, shares issued (in shares)	3,906	3,906
Preferred stock, shares outstanding (in shares)	3,906	3,906
Preferred stock, liquidation	$ 3,906	$ 3,906

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2018
Revenue
Net product sales	$ 5,805	$ 5,703	$ 13,396	$ 10,098
Total revenue	5,805	5,703	13,396	10,098
Operating expenses
Cost of product sales	808	551	1,524	1,051
Research and development	8,781	22,043	17,964	43,287
Selling, general and administrative	8,677	11,323	16,829	23,643
Total operating expenses	18,266	33,917	36,317	67,981
Loss from operations	(12,461)	(28,214)	(22,921)	(57,883)
Interest expense	(2,470)	(2,806)	(4,876)	(5,535)
Interest income	32	604	222	1,317
Other income—related party	0	0	4,085	0
Other expense	(693)	0	(693)	0
Total other income (expense), net	(3,131)	(2,202)	(1,262)	(4,218)
Net loss	$ (15,592)	$ (30,416)	$ (24,183)	$ (62,101)
Net loss per share, basic and diluted (usd per share)	$ (0.57)	$ (1.12)	$ (0.89)	$ (2.29)
Weighted-average common shares outstanding - basic and diluted (in shares)	27,326	27,108	27,282	27,071

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Preferred Stock [Member]Series C-1 Convertible Preferred Stock [Member]	Preferred Stock [Member]Series F Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings	Cumulative Effect, Period of Adoption, Adjustment [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	$ 35,921	$ 3,906	$ 2,737	$ 3	$ 950,258	$ (920,983)	$ 0	$ (160)	$ 160
Beginning Balance (in shares) at Dec. 31, 2018		4,000	3,000	26,259,000
Beginning Balance at Dec. 31, 2018	35,921	$ 3,906	$ 2,737	$ 3	950,258	(920,983)	0	(160)	160
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,782				6,782
Issuance of common stock under ESPP (in shares)				52,000
Net proceeds from issuance of common stock under ESPP	283				283
Net loss	(31,685)					(31,685)
Issuance of common stock for conversion of Series F Preferred Stock (in shares)			(3,000)	782,000
Issuance of common stock for conversion of Series F Preferred Stock			$ (2,737)		2,737
Cumulative-effect adjustment from adoption of ASU 2018-07	11,301	$ 3,906	$ 0	$ 3	959,900	(952,508)	0	(160)	160
Ending Balance (in shares) at Mar. 31, 2019		4,000	0	27,093,000
Ending Balance at Mar. 31, 2019	11,301	$ 3,906	$ 0	$ 3	959,900	(952,508)
Beginning Balance (in shares) at Dec. 31, 2018		4,000	3,000	26,259,000
Beginning Balance at Dec. 31, 2018	35,921	$ 3,906	$ 2,737	$ 3	950,258	(920,983)	0	(160)	160
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(62,101)
Cumulative-effect adjustment from adoption of ASU 2018-07	(12,593)	$ 3,906	$ 0	$ 3	966,422	(982,924)	$ 0	$ (160)	$ 160
Ending Balance (in shares) at Jun. 30, 2019		4,000	0	27,125,000
Ending Balance at Jun. 30, 2019	(12,593)	$ 3,906	$ 0	$ 3	966,422	(982,924)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	11,301	$ 3,906	$ 0	$ 3	959,900	(952,508)
Beginning Balance (in shares) at Mar. 31, 2019		4,000	0	27,093,000
Beginning Balance at Mar. 31, 2019	11,301	$ 3,906	$ 0	$ 3	959,900	(952,508)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,321
Issuance of common stock under ESPP (in shares)				32,000
Net proceeds from issuance of common stock under ESPP	201				201
Net loss	(30,416)					(30,416)
Cumulative-effect adjustment from adoption of ASU 2018-07	(12,593)	$ 3,906	$ 0	$ 3	966,422	(982,924)
Ending Balance (in shares) at Jun. 30, 2019		4,000	0	27,125,000
Ending Balance at Jun. 30, 2019	(12,593)	$ 3,906	$ 0	$ 3	966,422	(982,924)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	(12,593)	3,906	0	3	966,422	(982,924)
Cumulative-effect adjustment from adoption of ASU 2018-07	(55,990)	$ 3,906	$ 0	$ 3	977,432	(1,037,331)
Beginning Balance (in shares) at Dec. 31, 2019		4,000	0	27,195,000
Beginning Balance at Dec. 31, 2019	(55,990)	$ 3,906	$ 0	$ 3	977,432	(1,037,331)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,407
Exercise of stock options for common stock (in shares)				44,000
Net proceeds from issuance of common stock under 2013 Equity Plan	305				305
Issuance of common stock under ESPP (in shares)				38,000
Net proceeds from issuance of common stock under ESPP	200				200
Net loss	(8,591)					(8,591)
Cumulative-effect adjustment from adoption of ASU 2018-07	(61,669)	$ 3,906	$ 0	$ 3	980,344	(1,045,922)
Ending Balance (in shares) at Mar. 31, 2020		4,000	0	27,277,000
Ending Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 0	$ 3	980,344	(1,045,922)
Beginning Balance (in shares) at Dec. 31, 2019		4,000	0	27,195,000
Beginning Balance at Dec. 31, 2019	(55,990)	$ 3,906	$ 0	$ 3	977,432	(1,037,331)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	$ 3,997
Exercise of stock options for common stock (in shares)	94,219
Net loss	$ (24,183)
Cumulative-effect adjustment from adoption of ASU 2018-07	(75,212)	$ 3,906	$ 0	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4,000	0	27,359,000
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 0	$ 3	982,393	(1,061,514)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	(61,669)	$ 3,906	$ 0	$ 3	980,344	(1,045,922)
Beginning Balance (in shares) at Mar. 31, 2020		4,000	0	27,277,000
Beginning Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 0	$ 3	980,344	(1,045,922)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,590				1,590
Exercise of stock options for common stock (in shares)				50,000
Net proceeds from issuance of common stock under 2013 Equity Plan	300				300
Issuance of common stock under ESPP (in shares)				32,000
Net proceeds from issuance of common stock under ESPP	159				159
Net loss	(15,592)					(15,592)
Cumulative-effect adjustment from adoption of ASU 2018-07	(75,212)	$ 3,906	$ 0	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4,000	0	27,359,000
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 0	$ 3	982,393	(1,061,514)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	$ (75,212)	$ 3,906	$ 0	$ 3	$ 982,393	$ (1,061,514)

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Operating activities
Net loss	$ (15,592)	$ (8,591)	$ (30,416)	$ (31,685)	$ (24,183)	$ (62,101)	$ (62,101)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	1,590	2,407	6,321	6,782	3,997
Share-based compensation expense						13,103
Depreciation and amortization expense					1,798	2,263
Loss on disposal of equipment					904	15
Unrealized gains on short-term investments					(63)	0
Non-cash interest expense					3,392	4,678
Non-cash rent expense					699	639
Changes in operating assets and liabilities:
Accounts receivable, net					1,117	(512)
Inventory, net					(909)	52
Prepaid expenses and other current assets					1,675	22
Accounts payable					(1,696)	(3,664)
Accrued expenses					(3,378)	974
Accrued payroll and related expenses					(2,591)	(3,429)
Lease liability					(1,357)	(1,241)
Net cash used for operating activities					(20,595)	(49,201)
Investing activities
Proceeds from the sale of property and equipment					2,860	0
Purchases of property and equipment					0	(441)
Purchases of short-term investments					(2,999)	0
Net cash used for investing activities					(139)	(441)
Financing activities
Net proceeds from issuance of common stock under 2013 Equity Plan					605	0
Net proceeds from issuance of common stock under ESPP					359	484
Net cash provided by financing activities					964	484
Net decrease in cash and restricted cash					(19,770)	(49,158)
Cash and restricted cash at beginning of period		88,729		173,513	88,729	173,513
Cash and restricted cash at end of period	68,959		124,355		68,959	124,355	173,513
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series F Convertible Preferred Stock into common stock					0	2,737
Cumulative-effect adjustment from adoption of ASU 2018-07								$ 0		$ (160)
Initial recognition of right-of-use lease asset					0	16,798
Reconciliation of cash and restricted cash to the condensed consolidated balance sheets
Cash								68,353	$ 87,820	123,446
Restricted cash								606		909
Total cash and restricted cash	$ 68,959	$ 88,729	$ 124,355	$ 173,513	$ 68,959	$ 124,355	$ 173,513	$ 68,959	$ 88,729	$ 124,355

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , filed with the SEC on March 2, 2020 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ (deficit) equity or cash flows. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated balance sheet as of December 31, 2019 contained in the Form 10-K. Summary of Significant Accounting Policies During the six months ended June 30, 2020 , other than the short-term investments policy described below, there have been no changes to the Company’s significant accounting policies as described in the Form 10-K. Short-term investments Short-term investments are comprised of marketable equity securities that are “available-for-sale,” as such term is defined by the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 320. Marketable equity securities are classified as current assets. Short-term investments are measured at fair value, and unrealized gains and losses are recorded in other income (expense), net in the consolidated statements of operations. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits. During the six months ended June 30, 2020 , 409 hospitals in the U.S. purchased GIAPREZA. Hospitals purchase our products through a network of specialty and wholesale distributors (“Customers”). The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute GIAPREZA, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major Customers, each of which comprised 10% or more of its U.S. net product sales: U.S. Net Product Sales Accounts Receivable Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 As of June 30, 2020 Customer A 38 % 38 % 22 % Customer B 33 % 31 % 41 % Customer C 25 % 29 % 33 % Total 96 % 98 % 96 % Revenue Recognition The Company has adopted FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. There have been no contract assets or liabilities recorded to date relating to product sales. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: • Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers. • Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers. • Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers. • Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Recent Accounting Pronouncements Management has considered all recent accounting pronouncements and has concluded that there are no recently issued accounting pronouncements that may have a material effect on the Company’s results of operations, financial condition or cash flows based on current information.

Business

Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	Business La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA TM (angiotensin II) for injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (“Tetraphase”), a biopharmaceutical company focused on commercializing its novel tetracycline, XERAVA TM (eravacycline), to treat serious and life-threatening infections, for $43 million in upfront cash plus potential future cash payments of up to $16 million . XERAVA for injection is a novel fluorocycline of the tetracycline class of antibacterials that is approved by the FDA for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older . See Note 12. As of June 30, 2020 and December 31, 2019 , the Company had cash and short-term investments of $71.4 million and $87.8 million , respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and short-term investments will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”).

Net Loss per Share (Notes)

Net Loss per Share (Notes)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock, stock options and warrants are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June 30, 2020 and 2019 , there were 10.2 million and 14.0 million potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive.

Balance Sheet Account Details

Balance Sheet Account Details	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Details	Balance Sheet Details Restricted Cash Restricted cash as of June 30, 2020 and December 31, 2019 represents a standby letter of credit for the Company’s building lease in lieu of a security deposit during the term of such lease (see Note 6). There is a requirement to maintain $0.6 million of cash collateral in an account pledged as security for such letter of credit. Inventory, Net Inventory, net consisted of the following (in thousands): June 30, December 31, Work-in-process $ 1,801 $ 1,505 Finished goods 1,319 706 Total inventory, net $ 3,120 $ 2,211 As of June 30, 2020 and December 31, 2019 , total inventory is recorded net of inventory reserves of $0.2 million and $0.1 million , respectively. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, Leasehold improvements $ 14,504 $ 14,504 Furniture and fixtures 2,549 2,598 Computer hardware 1,296 1,296 Software 733 733 Lab equipment — 9,665 Total property and equipment, gross 19,082 28,796 Accumulated depreciation and amortization (6,255 ) (10,407 ) Total property and equipment, net $ 12,827 $ 18,389 Accrued Expenses Accrued expenses consisted of the following (in thousands): June 30, December 31, Accrued interest expense $ 3,530 $ 2,692 Accrued manufacturing costs 1,369 1,339 Accrued clinical study costs 815 3,496 Accrued other 1,058 1,785 Total accrued expenses $ 6,772 $ 9,312

Other Income_Related Party (Not

Other Income—Related Party (Notes)	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Other Income—Related Party	Other Income—Related Party The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the six months ended June 30, 2020 , the Company received distributions of $4.1 million in connection with this profits interest.

Commitments and Contingencies C

Commitments and Contingencies Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Commitments On December 29, 2016, the Company entered into an agreement with BMR-Axiom LP (the “Landlord”) to lease office and laboratory space as its corporate headquarters located at 4550 Towne Centre Court, San Diego, California (the “Lease”) for a period of 10 years commencing on October 30, 2017 (the “Initial Lease Term”). The Company has an option to extend the Lease for an additional 5 years at the end of the Initial Lease Term. The Company provided a standby letter of credit for $0.9 million in lieu of a security deposit. This amount decreased to $0.6 million after year two of the Initial Lease Term and will decrease to $0.3 million after year 5 of the Initial Lease Term. As of June 30, 2020 , $0.6 million of cash was pledged as collateral for such letter of credit and recorded as restricted cash. The annual rent under the Lease is subject to escalation during the term. In addition to rent, the Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises. The Lease contains customary default provisions, representations, warranties and covenants. The Lease is classified as an operating lease. Future minimum lease payments under the Lease as of June 30, 2020 are as follows (in thousands): 2020 $ 2,039 2021 4,174 2022 4,294 2023 4,417 2024 4,544 Thereafter 13,590 Total future minimum lease payments 33,058 Less: discount (5,168 ) Total lease liability $ 27,890 The Company recorded a lease liability for the Lease based on the present value of the Lease payments over the Initial Lease Term, discounted using the Company’s incremental borrowing rate. The Company recorded a corresponding right-of-use lease asset based on the lease liability, adjusted for incentives received prior to the Lease commencement date. The option to extend the Initial Lease Term was not recognized as a part of either the Company’s lease liability or right-of-use lease asset. Lease expense was $0.7 million and $1.4 million for the three and six months ended June 30, 2020 , respectively, and for the same periods in 2019 . Amortization for the right-of-use lease asset was $0.4 million and $0.7 million for the three and six months ended June 30, 2020 , respectively, and was $0.3 million and $0.6 million for the three and six months ended June 30, 2019 , respectively. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

Deferred Royalty Obligation

Deferred Royalty Obligation	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Deferred Royalty Obligation	Deferred Royalty Obligation In May 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10% . Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million . The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA. On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million , net of issuance costs of $0.7 million . For the three months ended June 30, 2020 and 2019 , the Company recognized interest expense, including amortization of the obligation discount, of $2.5 million and $2.8 million , respectively. For the six months ended June 30, 2020 and 2019 , the Company recognized interest expense, including amortization of the obligation discount, of $4.9 million and $5.5 million , respectively. The carrying value of the deferred royalty obligation as of June 30, 2020 was $124.4 million , net of unamortized obligation discount of $0.6 million , and was classified as noncurrent. The related accrued interest expense was $18.8 million and $15.5 million as of June 30, 2020 and December 31, 2019 , respectively, of which $15.3 million and $12.8 million was classified as other noncurrent liabilities, respectively. During the three and six months ended June 30, 2020 , the Company made royalty payments to HCR of $0.8 million and $1.5 million , respectively, and, as of June 30, 2020 , the Company recorded royalty obligations payable of $0.6 million in accrued expenses. The deferred royalty obligation is classified as Level 3 in the ASC 820-10, three-tier fair value hierarchy, and its carrying value approximates fair value. Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of June 30, 2020 and December 31, 2019 . Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations.

George Washington University Li

George Washington University License (Notes)	6 Months Ended
	Jun. 30, 2020
Research and Development [Abstract]
George Washington University License	George Washington University License In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was amended and restated on March 1, 2016 (the “GW License”) and subsequently assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the EC’s approval of GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of GIAPREZA. The patents and patent applications covered by the GW License are expected to expire between 2029 and 2034, and the obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA.

Shareholders_ Deficit Sharehold

Shareholders’ Deficit Shareholders’ Deficit	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Shareholders’ Deficit	Shareholders’ Equity Preferred Stock As of June 30, 2020 and December 31, 2019 , 3,906 shares of Series C-1 2 Convertible Preferred Stock (“Series C-1 2 Preferred”) were issued, outstanding and convertible into 6,735,378 shares of common stock. In January 2019, the Company issued 782,031 shares of common stock upon the conversion of 2,737 shares of Series F Convertible Preferred Stock. As of June 30, 2020 and December 31, 2019 , there were no shares of Series F Convertible Preferred Stock issued and outstanding. Warrants As of June 30, 2020 and December 31, 2019 , the Company had outstanding warrants to purchase 10,000 shares of common stock. The Company did not recognize share-based compensation expense for these outstanding warrants for the three and six months ended June 30, 2020 and 2019 .

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans 2013 Equity Incentive Plan A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of June 30, 2020 , 5,940,653 shares of common stock remained available for future grants under the 2013 Equity Plan. 2018 Employee Stock Purchase Plan A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2020 , 499,805 shares of common stock remained available for future grants under the ESPP. Equity Awards The activity related to equity awards, which are comprised of stock options and inducement grants, during the six months ended June 30, 2020 is summarized as follows: Equity Awards Weighted- average Exercise Price per Share Weighted- average Remaining Contractual Term Aggregate Outstanding at December 31, 2019 5,616,840 $ 19.50 Granted 806,923 $ 5.27 Exercised (94,219 ) $ 6.42 Cancelled/forfeited (2,883,533 ) $ 19.43 Outstanding at June 30, 2020 3,446,011 $ 16.59 5.87 years $ 35,037 Exercisable at June 30, 2020 2,144,609 $ 20.84 4.27 years $ — Share-based Compensation Expense The classification of share-based compensation expense is summarized as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and development $ 964 $ 3,960 $ 2,527 $ 7,893 Selling, general and administrative 626 2,361 1,470 5,210 Total share-based compensation expense $ 1,590 $ 6,321 $ 3,997 $ 13,103 As of June 30, 2020 , total unrecognized share-based compensation expense related to unvested equity awards was $8.6 million , which is expected to be recognized over a weighted-average period of 2.2 years . As of June 30, 2020 , there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

Company-wide Realignment (Notes

Company-wide Realignment (Notes)	6 Months Ended
	Jun. 30, 2020
Restructuring and Related Activities [Abstract]
Company-wide Realignment	Company-wide Realignments

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisition of Tetraphase Pharmaceuticals, Inc. On June 24, 2020, La Jolla entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections, and TTP Merger Sub, Inc., a wholly owned subsidiary of La Jolla. On July 28, 2020, La Jolla completed its acquisition of Tetraphase for $43 million in upfront cash plus potential future cash payments of up to $16 million pursuant to contingent value rights (“CVRs”). The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million ; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. Following the acquisition, Tetraphase became a wholly owned subsidiary of La Jolla. The acquisition of Tetraphase will be accounted for as a business combination pursuant to FASB ASC Topic 805.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 , filed with the SEC on March 2, 2020
Principles of Consolidation	The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates	The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ (deficit) equity or cash flows. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated balance sheet as of December 31, 2019 contained in the Form 10-K.
Short-term investments	Short-term investments Short-term investments are comprised of marketable equity securities that are “available-for-sale,” as such term is defined by the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 320. Marketable equity securities are classified as current assets. Short-term investments are measured at fair value, and unrealized gains and losses are recorded in other income (expense), net in the consolidated statements of operations.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.
Revenue Recognition	Revenue Recognition The Company has adopted FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. There have been no contract assets or liabilities recorded to date relating to product sales. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: • Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers. • Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers. • Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers. • Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management has considered all recent accounting pronouncements and has concluded that there are no recently issued accounting pronouncements that may have a material effect on the Company’s results of operations, financial condition or cash flows based on current information.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedules of Concentration of Risk	The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major Customers, each of which comprised 10% or more of its U.S. net product sales: U.S. Net Product Sales Accounts Receivable Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 As of June 30, 2020 Customer A 38 % 38 % 22 % Customer B 33 % 31 % 41 % Customer C 25 % 29 % 33 % Total 96 % 98 % 96 %

Balance Sheet Account Details (

Balance Sheet Account Details (Tables)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory, net consisted of the following (in thousands): June 30, December 31, Work-in-process $ 1,801 $ 1,505 Finished goods 1,319 706 Total inventory, net $ 3,120 $ 2,211
Property, Plant and Equipment	Property and equipment, net consisted of the following (in thousands): June 30, December 31, Leasehold improvements $ 14,504 $ 14,504 Furniture and fixtures 2,549 2,598 Computer hardware 1,296 1,296 Software 733 733 Lab equipment — 9,665 Total property and equipment, gross 19,082 28,796 Accumulated depreciation and amortization (6,255 ) (10,407 ) Total property and equipment, net $ 12,827 $ 18,389
Accrued Expenses	Accrued expenses consisted of the following (in thousands): June 30, December 31, Accrued interest expense $ 3,530 $ 2,692 Accrued manufacturing costs 1,369 1,339 Accrued clinical study costs 815 3,496 Accrued other 1,058 1,785 Total accrued expenses $ 6,772 $ 9,312

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments under the Lease as of June 30, 2020 are as follows (in thousands): 2020 $ 2,039 2021 4,174 2022 4,294 2023 4,417 2024 4,544 Thereafter 13,590 Total future minimum lease payments 33,058 Less: discount (5,168 ) Total lease liability $ 27,890

Equity Incentive Plans Equity I

Equity Incentive Plans Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Equity award activity	The activity related to equity awards, which are comprised of stock options and inducement grants, during the six months ended June 30, 2020 is summarized as follows: Equity Awards Weighted- average Exercise Price per Share Weighted- average Remaining Contractual Term Aggregate Outstanding at December 31, 2019 5,616,840 $ 19.50 Granted 806,923 $ 5.27 Exercised (94,219 ) $ 6.42 Cancelled/forfeited (2,883,533 ) $ 19.43 Outstanding at June 30, 2020 3,446,011 $ 16.59 5.87 years $ 35,037 Exercisable at June 30, 2020 2,144,609 $ 20.84 4.27 years $ —
Share-based compensation expense	The classification of share-based compensation expense is summarized as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and development $ 964 $ 3,960 $ 2,527 $ 7,893 Selling, general and administrative 626 2,361 1,470 5,210 Total share-based compensation expense $ 1,590 $ 6,321 $ 3,997 $ 13,103

Business (Narrative) (Details)

Business (Narrative) (Details) - USD ($) $ in Millions	Jul. 28, 2020	Jun. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Cash and short-term investments		$ 71.4	$ 87.8
Subsequent Event [Member] | Tetraphase Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Upfront cash for acquisition	$ 43
Future cash payments	16
Additional aggregate payments	$ 16

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Schedule of Concentration Risk) (Details)	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2020
U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		96.00%	98.00%
Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	96.00%
Customer A | U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		38.00%	38.00%
Customer A | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	22.00%
Customer B | U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		33.00%	31.00%
Customer B | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	41.00%
Customer C | U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		25.00%	29.00%
Customer C | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	33.00%

Net Loss per Share (Details)

Net Loss per Share (Details) - shares shares in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants (in shares)	10.2	14

Balance Sheet Account Details

Balance Sheet Account Details (Narrative) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Restricted Cash and Cash Equivalents Items [Line Items]
Inventory reserves	$ 200,000	$ 100,000
4550 Towne Centre Court, San Diego, California | Financial Standby Letter of Credit | Letter of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Cash collateral as security	$ 600,000

Balance Sheet Account Details_2

Balance Sheet Account Details (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Work-in-process	$ 1,801	$ 1,505
Finished goods	1,319	706
Total inventory, net	$ 3,120	$ 2,211

Balance Sheet Account Details_3

Balance Sheet Account Details (Property Plant and Equipment) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 19,082	$ 28,796
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	6,255	10,407
Property, Plant and Equipment, Net	12,827	18,389
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	0	9,665
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,549	2,598
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,296	1,296
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	733	733
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 14,504	$ 14,504

Balance Sheet Account Details_4

Balance Sheet Account Details (Summary of Accrued Expenses) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued interest expense	$ 3,530	$ 2,692
Accrued clinical study costs	815	3,496
Accrued manufacturing costs	1,369	1,339
Accrued other	1,058	1,785
Total accrued expenses	$ 6,772	$ 9,312

Other Income_Related Party (Det

Other Income—Related Party (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2018
Related Party Transactions [Abstract]
Other income—related party	$ 0	$ 0	$ 4,085	$ 0

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Oct. 30, 2022	Dec. 31, 2019	Oct. 30, 2019	Dec. 29, 2016
Lessee, Lease, Description [Line Items]
Term of lease contract								10 years
Renewal term of lease contract								5 years
Cash collateral as security	$ 606		$ 606			$ 909
Lease expense	700	$ 700	1,400	$ 1,400
Right of use asset amortization	$ 400	$ 300	$ 700	$ 600
Standby Letters of Credit
Lessee, Lease, Description [Line Items]
Security deposit							$ 600	$ 900
Forecast | Standby Letters of Credit
Lessee, Lease, Description [Line Items]
Security deposit					$ 300

Commitments and Contingencies_3

Commitments and Contingencies (Lease liability maturity) (Details) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
2019	$ 2,039
2020	4,174
2021	4,294
2022	4,417
2023	4,544
Thereafter	13,590
Total future minimum lease payments	33,058
Less: discount	(5,168)
Total lease liability	$ 27,890

Deferred Royalty Obligation (De

Deferred Royalty Obligation (Details) - USD ($)	May 10, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Deferred royalty obligation, net		$ 124,406,000		$ 124,406,000		$ 124,379,000
Interest expense		2,500,000	$ 2,800,000	4,900,000	$ 5,500,000
Royalty Obligation Payable		600,000		600,000
HealthCare Royalty Partners
Debt Instrument [Line Items]
Proceeds from royalty agreement	$ 125,000,000
Required payment for breach of agreement, payment one	125,000,000
Required payment for breach of agreement, payment two	225,000,000
HealthCare Royalty Partners | Loans Payable | Royalty Financing Agreement
Debt Instrument [Line Items]
Deferred royalty obligation, net	125,000,000	124,400,000		124,400,000
Debt issuance costs	$ 700,000
Unamortized debt discount		600,000		600,000
Accrued interest expense		18,800,000		18,800,000		15,500,000
Royalty payments		800,000		1,500,000
HealthCare Royalty Partners | Period One
Debt Instrument [Line Items]
Maximum potential royalty payout	10.00%
HealthCare Royalty Partners | Period Two
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%
HealthCare Royalty Partners | Payout Period
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%
Other Noncurrent Liabilities | HealthCare Royalty Partners | Loans Payable | Royalty Financing Agreement
Debt Instrument [Line Items]
Accrued interest expense		$ 15,300,000		$ 15,300,000		$ 12,800,000

George Washington University _2

George Washington University License (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
GeorgeWashington [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment	$ 0.5

Shareholders_ Deficit (Details)

Shareholders’ Deficit (Details) - shares	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Jan. 31, 2019
Series C-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)	3,906	3,906	3,906
Convertible Preferred Stock, Shares Reserved for Future Issuance	6,735,378		6,735,378
Common Stock [Member]
Class of Stock [Line Items]
Shares issued upon conversion (in share)				782,031
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)				2,737
Common Stock [Member]
Class of Stock [Line Items]
Warrants outstanding (in shares)	10,000		10,000

Equity Incentive Plans (Narrati

Equity Incentive Plans (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2020USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized share-based compensation expense | $	$ 8.6
Recognized weighted average period	2 years 2 months 12 days
2013 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance	9,600,000
Shares available for grant (in shares)	5,940,653
2018 Employee Stock Purchase Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance	750,000
Shares available for grant (in shares)	499,805

Equity Incentive Plans (Stock O

Equity Incentive Plans (Stock Option Activity) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020
Shares Underlying Stock Options
Outstanding beginning balance, Shares underlying stock options and restricted stock awards (in shares)	5,616,840
Granted, Shares underlying stock options and restricted stock awards (in shares)	806,923
Exercised, Shares underlying stock options and restricted stock awards (in shares)	94,219
Forfeited, Shares underlying stock options and restricted stock awards (in shares)	(2,883,533)
Outstanding ending balance, Shares underlying stock options and restricted stock awards (in shares)	3,446,011
Weighted- Average Exercise Price per Share
Outstanding beginning balance, Weighted - average exercise price (usd per share)	$ 19.50
Granted, Weighted - average exercise price (usd per share)	5.27
Exercised, Weighted - average exercise price (usd per share)	6.42
Forfeited, Weighted - average exercise price (usd per share)	19.43
Outstanding ending balance, Weighted - average exercise price (usd per share)	$ 16.59
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 10 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 35,037
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Shares	2,144,609
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 20.84
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 3 months 7 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 0

Equity Incentive Plans (Share-b

Equity Incentive Plans (Share-based Compensation Expense) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,590,000	$ 6,321,000	$ 3,997,000	$ 13,103,000
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	964,000	3,960,000	2,527,000	7,893,000
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 626,000	$ 2,361,000	$ 1,470,000	$ 5,210,000

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Reversal of non-cash-stock-based compensation expense	$ 0.4		$ 0.9
Restructuring Costs	4.1	$ 5.8	$ 5.8
Payments for Restructuring	0.7	4.8
Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3.4	$ 1

Subsequent Events (Details)

Subsequent Events (Details) - Tetraphase Pharmaceuticals, Inc. [Member] - Subsequent Event [Member] $ / shares in Units, $ in Millions	Jul. 28, 2020USD ($)$ / shares
Subsequent Event [Line Items]
Upfront cash for acquisition	$ 43
Future cash payments	16
Additional aggregate payments	$ 16
Common Stock [Member]
Subsequent Event [Line Items]
Share price (in usd per share) | $ / shares	$ 2
Common Stock Issued In Nov 2019 [Member]
Subsequent Event [Line Items]
Share price (in usd per share) | $ / shares	2.68
Common Stock Issued In Jan 2020 [Member]
Subsequent Event [Line Items]
Share price (in usd per share) | $ / shares	$ 2.69
Agreement 1 [Member]
Subsequent Event [Line Items]
Proceeds from businesses and interest in affiliates	$ 2.5
Net sales from related parties	20
Agreement 2 [Member]
Subsequent Event [Line Items]
Proceeds from businesses and interest in affiliates	4.5
Net sales from related parties	35
Agreement 3 [Member]
Subsequent Event [Line Items]
Proceeds from businesses and interest in affiliates	9
Net sales from related parties	$ 55